Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for people with serious diseases, often with limited or no therapeutic options. It operates in neuroscience and oncology, with marketed medicines and product candidates from early to late-stage development. It explores small molecules and biologics, innovative delivery technologies and cannabinoid science. Its growth strategy centers on commercial launches, R&D productivity, strategic corporate development and financial performance, under a "Vision 2025" plan emphasizing commercial execution, pipeline productivity and operational excellence. It targets patient populations with high unmet needs, using an efficient, scalable commercial model.

In neuroscience, the company markets Xywav (a lower-sodium oxybate for narcolepsy cataplexy or excessive daytime sleepiness and for idiopathic hypersomnia in adults), Xyrem (sodium oxybate for narcolepsy) and Epidiolex/Epidyolex (cannabidiol for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex). Epidiolex came with the $7.2 billion acquisition of GW Pharmaceuticals in May 2021. In oncology, its products are Zepzelca (lurbinectedin for metastatic small cell lung cancer, licensed from PharmaMar), Rylaze (recombinant erwinia asparaginase for acute lymphoblastic leukemia and lymphoblastic lymphoma), Vyxeos (for certain newly diagnosed acute myeloid leukemias) and Defitelio (for hepatic veno-occlusive disease after stem cell transplantation). It also supports Sativex in 29 markets outside the U.S. and divested Sunosi to Axsome in 2022. 2022 net product sales were: Xyrem $1.0 billion (28% of total), Xywav $958.4 million (26%), Epidiolex/Epidyolex $736.4 million (20%), Rylaze $281.7 million (8%), Zepzelca $269.9 million (7%), Defitelio $194.3 million (5%) and Vyxeos $128.0 million (4%). Products launched or acquired since 2019 generated 63% of 2022 net product sales, compared with 75% of 2018 sales coming from Xyrem alone.

Its customers are patients with conditions such as narcolepsy, idiopathic hypersomnia, childhood-onset epilepsies, small cell lung cancer, leukemias and post-transplant liver complications, along with the physicians who treat them. Sales are concentrated in the U.S., with approvals and launches in Canada, the EU, Great Britain and other markets such as Israel, Australia and New Zealand. Xywav had about 10,300 active patients at the end of 2022 and had benefit coverage for about 90% of commercial lives, including agreements with all three major U.S. pharmacy benefit managers. Xyrem is commercialized in Europe and other territories by UCB Pharma under a license and distribution agreement.

In the U.S., Xywav and Xyrem are sold under an FDA-required risk evaluation and mitigation strategy. All product is dispensed through a single central pharmacy, Express Scripts Specialty Distribution Services, under exclusive agreements running through December 1, 2024, and may not be stocked in retail pharmacies. Zepzelca is in-licensed from PharmaMar for the U.S. and Canada. The company holds orphan drug exclusivity for several products, including Xywav through 2027 in narcolepsy and 2028 in idiopathic hypersomnia. The text does not describe its manufacturing, competitors or headquarters.